Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118687 · ClinicalTrials.gov registry record
Human Immunome Program
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 2
- Enrollment target
NCT03118687: Completed study, sponsored by Vanderbilt University Medical Center.
NCT03118687 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03118687 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The Human Immunome Program is a large-scale, open-source effort seeking to fill a major gap in our knowledge of the immune system. The power of the immune system to fight disease lies in its ability recognize and adapt to an astonishing range of threats from viruses, parasites and bacteria to cancer cells. Underlying this ability is a vast but specific set of genes and molecular structures known as the human immunome, or the "parts list" of the immune system. This study aims to decipher the genetic sequences that make up this part list and link it to information about a person's microbiome composition and characteristics such as health history, race, and demographics over time. This information, made freely available to the public for use in research in de-identified form, will allow investigators to answer a wide variety of different questions about immune system function. This could transform how we diagnose, prevent and treat disease though the identification of new biomarkers while enabling highly targeted, computationally designed vaccines and therapies that reduce time and risk of product development.
Primary Outcome
The B and T cell receptor repertoire will be sequenced. The sequencing will continue until no new unique sequences appear.
Interventions
- OTHER Biospecimen and survey collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-06-18 |
What the finished NCT03118687 record still lists
NCT03118687 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biospecimen and survey collection is the first listed.
NCT03118687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03118687 about?
NCT03118687 is a clinical study titled "Human Immunome Program". The Human Immunome Program is a large-scale, open-source effort seeking to fill a major gap in our knowledge of the immune system. The power of the immune system to fight disease lies in its ability recognize and adapt to an astonishing range of threats from viruses, parasites and bacteria to cancer...
What is the current status of trial NCT03118687?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2017-07-01. Estimated completion is 2020-06-18.
What interventions are being tested in trial NCT03118687?
The interventions under investigation include: Biospecimen and survey collection (OTHER).
Who is sponsoring clinical trial NCT03118687?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI